May 2018 Volume 14, Issue 5
Volume 14, Issue 5 | May 2018
May 2018
In this Issue
Feature
ISSCR 2018 show preview: Heading Down Under to bring up matters about stem cells
International Society for Stem Cell Research’s 2018 annual meeting to be hosted in AustraliaASCO 2018 show preview: Deep dish--ASCO brings cancer researchers to Chicago
Annual clinical cancer research meeting dives deep into discoverySpecial Focus on CRISPR: Regarding lipids and CRISPR
On one side, the gene-editing technology tackles lipids; on the other, it uses them for transportation; plus additional news of CRISPR research and technology and a bonus guest commentarySpecial Reports
Special Report on Epigenetics: More than a number
Epigenetics shows that not all aging is created equalDiscovery
Gems in the ‘junk’
Noncoding mutations found to be a major mechanism in cancerTSRI makes headway in neurology
Two new discoveries have been made regarding Parkinson’s disease and depressionA new arrow in the treatment quiver
Boosting adenosine levels with a new stem cell population could help to treat epilepsyC4XD signs license deal with Indivior for addiction program
Company receives $10 million up front, with potential milestones totaling $284 million plus royaltiesBioAscent establishes integrated drug discovery services offering
New CSO hired to lead company’s extended capabilities in medicinal chemistry and in-vitro biosciencesClinical Trials
Berubicin blasts glioblastoma
The anthracycline drug is the only one of its class engineered to attack tumor cells at the siteA setback, but not for long
Serlopitant misses primary and secondary efficacy endpoints, but Menlo continues with development programPositive results for novel antiviral in HBV
Assembly Biosciences to launch Phase 2a studies in summer 2018Seladelpar impresses at International Liver Congress
CymaBay’s PPARδ agonist reduces alkaline phosphatase levels in PBC patientsGetting you where you need to go
ClinOne announces integration with Lyft and Uber for free patient transportation to study sitesResearch & Development
The chip craze continues
Research teams worldwide are working to harness the potential of organ-on-a-chip technologyClathrin collaboration
Microscopy shows how cells engulf nutrients and virusesRoswell Park data may link ovarian and testicular cancer
Men with testicular cancer more likely to have female relatives with ovarian cancerTSRI arm gets $34M from NIH
Scripps Translational Science Institute receives NIH Clinical and Translational Science AwardAgilent and BioTek join forces
Companies create an integrated metabolic analysis and imaging platformEditor's Focus
Editor’s focus: Navigating the gray areas
Gray literature isn't the same as peer-reviewed literature, but it doesn't need to be; however, we need to keep use of it in perspective and in balanceCommentary
Out of order: What lies beneath
Randomized, double-blinded, placebo-controlled clinical trials are the "gold standard" but let's remember that even gold can be tarnished and not all that glitters is truly goldGuest commentary: Implications of cGMP for CRISPR/Cas9 cellular therapy
CRISPR/Cas9 offers the hope of a cure for various maladies, including genetic diseases and cancers, but current Good Manufacturing Practices still matter in handling this therapeutic avenueContract Services
Frontage acquires Concord Biosciences
Deal will add preclinical, toxicology and agrochemical services to Frontage’s existing product development portfolioBoosting and complementing its DMPK
International CRO gobbles up drug transporter and drug-drug interaction specialist companyHelsinn wins across the board
Company takes first in all core categories at 2018 CMO Leadership AwardsBusiness & Government Policy
Predictive genomic medicine
NIH project aims to determine phenotype from genotype, match researchers to genes and variants of interestNovartis takes aim at SMA market with AveXis deal
Company is acquiring AveXis and its spinal muscular atrophy drug candidate for $8.7 billionNDA Group releases data comparing FDA and EMA
Information released ahead of annual DIA Europe meeting in BaselOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsMaking progress: A roundup of recent pharma/biotech milestones
News from AiCuris, Organovo, Catalyst Biosciences and Zosano PharmaPatent Docs: Federal Circuit suggests way out of subject matter eligibility morass
A tortured path on applying patent eligibility decisions finally offers some scant hope for better interpretation and understandingPreclinical
Repair and regeneration
Cell therapy study offers hope for Duchenne muscular dystrophyRhythm licenses RM-853 from Takeda
Oral GOAT inhibitor complements and expands efforts in Prader-Willi syndrome‘Tremendous potential’ against pancreatic cancer
Combination of immune agonists may fight one of the fastest-moving and deadliest of cancersTHR-149 shows efficacy vs. DME
ThromboGenics announces publication of preclinical data in The Journal of Medicinal ChemistryDiagnostics
Sample-to-insight pathogen testing improves
QIAGEN acquires molecular diagnostics company STAT-Dx and its multiplex technologiesA 'FIGHT' for life in gastric cancer
PGDx to develop companion diagnostic for Five Prime’s bemarituzumabIllumina, Loxo and companions
Deal expands Illumina’s oncology offerings for with a CDx version of TruSight Tumor 170 for solid tumorsMultiple studies show potential of T2’s diagnostics
Data indicate improved detection of sepsis-causing pathogens over blood culture-based diagnosticsQ&A
Q&A: A new option for oral anticoagulants
A chat with Espero BioPharma’s CEO reveals shortcomings of current standard of care and efforts to advance a better candidate
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Reliable fluid biomarkers strategies for clinical neuroscience research
Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Understanding drug impurities: types, sources, and analytical strategies
Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Discovering cutting-edge nitrosamine analysis in pharmaceuticals
New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
